Trial Profile
A randomized, double-blind, placebo controlled study to evaluate the effect of cisplatin/epinephrine injectable gel (product MPI 5010) when administered intratumorally for achievement of treatment goals in recurrent or refractory squamous cell carcinoma of the head and neck
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 21 Dec 2013
Price :
$35
*
At a glance
- Drugs Cisplatin/epinephrine (Primary)
- Indications Head and neck cancer
- Focus Registrational; Therapeutic Use
- 20 Sep 2005 New trial record.